PKM2 inhibitor (compound 3k): Selective Disruption of Cancer Metabolism

Executive Summary: PKM2 inhibitor (compound 3k) is a small molecule that selectively inhibits pyruvate kinase M2 (PKM2), a glycolytic enzyme highly expressed in tumor cells such as HCT116, Hela, and H1299. The compound demonstrates nanomolar to low micromolar potency (IC50 values 0.18–1.56 μM) in cancer cell lines, but shows markedly lower cytotoxicity in normal cells, indicating selective targeting. In vivo, oral administration in SK-OV-3 xenograft models significantly reduces tumor burden without major toxicity. Mechanistic studies and peer-reviewed research confirm the centrality of PKM2 in both cancer metabolism and immunometabolic reprogramming, broadening the relevance of this inhibitor to inflammation research (Wu et al., 2025). APExBIO supplies PKM2 inhibitor (compound 3k) as a reliable research reagent for oncology and immunometabolic workflows.

Biological Rationale

Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that catalyzes the conversion of phosphoenolpyruvate to pyruvate in the final step of glycolysis. PKM2 is preferentially expressed in embryonic and tumor tissues, distinguishing it from other pyruvate kinase isoforms (product information). Cancer cells rely on aerobic glycolysis (the Warburg effect) to support rapid proliferation and survival under hypoxic conditions. High PKM2 activity supports metabolic reprogramming, promoting anabolic growth and resistance to apoptosis. Recent studies show that PKM2 also modulates immune cell polarization and inflammatory responses, notably in macrophages, underscoring its role as a molecular node in cancer and inflammation (Wu et al., 2025). Targeting PKM2 thus offers an avenue to disrupt both tumor metabolism and immunometabolic signaling.

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) is a selective, reversible small molecule inhibitor with an IC50 of 2.95 μM against recombinant PKM2. By binding to the enzyme, it inhibits its catalytic activity, leading to blockade of glycolytic flux in PKM2-overexpressing cells (APExBIO). This results in reduced ATP production and accumulation of upstream metabolites, triggering metabolic stress and inducing autophagic cell death. In cancer cells, this translates to potent antiproliferative effects, while sparing normal cells with lower PKM2 dependence. In macrophages, inhibition of PKM2 can shift polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, as shown in recent models of acute pancreatitis (Wu et al., 2025). The compound does not directly target other pyruvate kinase isoforms, minimizing off-target effects.

Evidence & Benchmarks

• PKM2 inhibitor (compound 3k) exhibits an IC50 of 2.95 μM against PKM2 enzymatic activity in vitro (product information).
• Demonstrates potent antiproliferative effects in HCT116, Hela, and H1299 cancer cell lines with IC50 values of 0.18, 0.29, and 1.56 μM, respectively (product information).
• Shows markedly lower cytotoxicity towards normal BEAS-2B cells, confirming tumor-selective PKM2 targeting (product information).
• In SK-OV-3 ovarian cancer xenograft models, oral dosing at 5 mg/kg every two days for 31 days significantly reduces tumor volume and weight without major weight loss or organ toxicity (product information).
• In murine models of severe acute pancreatitis, PKM2 inhibition partially reverses the anti-inflammatory benefits of USP7 knockdown, confirming the central role of PKM2 in immunometabolic reprogramming (Wu et al., 2025).

For additional context, the article "PKM2 inhibitor (compound 3k): Selective Disruption of Cancer Metabolism" highlights the compound’s nanomolar activity and in vivo efficacy in ovarian cancer models; this article further elaborates the immunometabolic dimension established in recent peer-reviewed research. The aktpathway.com review focuses on translational oncology utility, whereas this dossier updates the mechanistic link to macrophage polarization. For immunometabolic research, see this workflow guide; the present article emphasizes validated in vivo endpoints and selectivity.

Applications, Limits & Misconceptions

PKM2 inhibitor (compound 3k) is validated for use as an antiproliferative agent in cancer research and as a tool for probing immunometabolic reprogramming. Its high selectivity for PKM2 makes it suitable for dissecting glycolytic dependency in cancer cell lines and for investigating macrophage phenotypic transitions in inflammation. The compound’s in vivo efficacy is demonstrated in ovarian cancer xenografts and in inflammatory disease models. However, its use is limited to research settings and is not approved for clinical application. Evidence for efficacy is strongest in models with high PKM2 expression; results may not extrapolate to tumors with low PKM2 or alternative metabolic adaptations. Effects in non-malignant tissues are limited, but off-target toxicity at high concentrations or prolonged exposure cannot be excluded.

Common Pitfalls or Misconceptions

• PKM2 inhibitor (compound 3k) is not pan-selective for all pyruvate kinase isoforms; activity is specific to PKM2 and efficacy in PKM1/PKL-dominant cells is limited.
• The compound is not recommended for ethanol- or water-based assays due to poor solubility; DMSO with gentle warming is required for optimal dissolution (product specification).
• PKM2 inhibition may not induce apoptosis in all cell types; autophagic pathways are more commonly triggered in glycolysis-dependent tumors.
• Results obtained in murine models may not fully predict human outcomes due to interspecies differences in PKM2 regulation and immune system responses.
• The inhibitor is not a direct immunosuppressant; its effects on inflammation are mediated via metabolic reprogramming, not by direct cytokine inhibition.

Workflow Integration & Parameters

• Stock preparation: Dissolve at ≥34.5 mg/mL in DMSO with gentle warming. Do not use ethanol or water as solvents (APExBIO).
• In vitro assays: Typical working concentrations range from 0.05 μM to 10 μM, depending on cell line PKM2 expression.
• In vivo xenograft dosing: 5 mg/kg by oral gavage every 2 days for 31 days shows efficacy in SK-OV-3 tumor-bearing BALB/c nude mice (product information).
• Storage: Store powder at -20°C. Prepared solutions should be used within days and protected from repeated freeze-thaw cycles.
• Immunometabolic studies: For macrophage polarization, co-treat with PKM2 inhibitor (compound 3k) during M1-inducing conditions to probe glycolytic dependency (Wu et al., 2025).

Conclusion & Outlook

PKM2 inhibitor (compound 3k) from APExBIO provides a potent and selective approach for targeting glycolytic metabolism in cancer and for dissecting the metabolic underpinnings of immune cell function. The compound’s robust selectivity, well-characterized in vitro and in vivo benchmarks, and effectiveness in both oncology and inflammation models position it as a valuable tool for translational research. Ongoing studies continue to clarify PKM2’s role across disease contexts, supporting further exploration of metabolic intervention strategies in cancer and immunology. No evidence currently supports direct clinical translation, but preclinical data strongly encourage continued investigation of PKM2 as a therapeutic target.